




The relative strengths and weaknesses of Sciclone Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sciclone Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Sciclone Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 418%, being 174% points above the market average of 245%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 195,733              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 30,838               |
| Liabilities, Current                        | 26,441               |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 13,325               |
| Other Compr. Net Income                     | -3,590               |
| Other Expenses                              | 96,084               |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 898                  |
| Other Revenues                              | 160,096              |
| Property and Equipment                      | 2,002                |
| Research and Development                    | 0                    |
| Selling, General and Administrative Expense | 34,181               |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 241,898              |
| Liabilities                  | 26,441               |
| Expenses                     | 130,265              |
| Revenues                     | 160,096              |
| Stockholders Equity          | 215,457              |
| Net Income                   | 30,729               |
| Comprehensive Net Income     | 28,934               |
| BaseVar                      | 281,594              |
| ECR before Limited Liability | 372%                 |
| Economic Capital Ratio       | 418%                 |